Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood
<p>Abstract</p> <p>Background</p> <p>In preparation for potential clinical development of Ab-01, an antagonistic antibody directed against the IL21R, studies were undertaken to address translational medicine needs that fall into four categories: 1) development of a phar...
Main Authors: | Young Deborah, LaVallie Edward R, Allen Scott W, Smith Michael F, Bree Andrea G, Guo Yongjing, Hill Andrew A, Weaver Amy A, Jain Sadhana, Arai Maya, Bloom Laird, Adkins Karissa, O'Toole Margot |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-05-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/8/1/51 |
Similar Items
-
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
by: Bechard Theresa, et al.
Published: (2010-05-01) -
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys
by: Spaulding Vikki, et al.
Published: (2010-04-01) -
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate.
by: Regina S Salvat, et al.
Published: (2015-01-01) -
Advances in the Development of Biotherapeutics
by: Pedro H. Oliveira, et al.
Published: (2015-01-01) -
The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant
by: Delphine L. Lauté-Caly, et al.
Published: (2019-01-01)